scholarly journals ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi19-vi19
Author(s):  
Scott Plotkin ◽  
Justin Jordan ◽  
Roberta Beauchamp ◽  
Alona Muzikansky ◽  
Anat Stemmer-Rachamimov ◽  
...  
Keyword(s):  
Phase 2 ◽  
Intermittent Schedule ◽  
Neurofibromatosis 2 ◽  
Phase 2 Study

scholarly journals RARE-19. MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi215-vi215
Author(s):  
Scott Plotkin ◽  
James Tonsgard ◽  
Nicole Ullrich ◽  
Jeffrey Allen ◽  
Jashri Blakeley ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Vestibular Schwannomas ◽  
Phase 2 ◽  
Neurofibromatosis 2 ◽  
Multicenter Phase ◽  
Phase 2 Study

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

2017 ◽  
Vol 1 ◽  
pp. s12
Author(s):  
Andrew Blauvelt ◽  
Craig Leonardi ◽  
Claus Zachariae ◽  
Russel Burge ◽  
Terri Ridenour ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Phase 2 ◽  
Chronic Plaque Psoriasis ◽  
Open Label ◽  
Phase 2 Study ◽  
Health Related

Abstract Not Available

Sign in / Sign up

Export Citation Format

Share Document